Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapivirine gel PK in HIV-1 seronegative adults
NCT03393468Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapivirine in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Dapivirine concentration in rectal fluid at 1 month, Dapivirine concentration in plasma at 1 month and 1 more. Started May 2018; status: completed.
02
Drugs
dapivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03393468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393468.